(Q37109214)

18 August 2017

1 reference

title

Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer (English)

1 reference

18 August 2017

angiogenesis inhibitor

1 reference

Rakesh K Jain

1

1 reference

PubMed ID

18337733

18 August 2017

language of work or name

English

0 references

publication date

1 April 2008

1 reference

18 August 2017

Nature Reviews Cancer

1 reference

18 August 2017

8

1 reference

18 August 2017

309-316

1 reference

18 August 2017

4

1 reference

https://scigraph.springernature.com/pub.10.1038/nrc2346

18 August 2017

0 references

cites work

Interstitial fluid pressure in intracranial tumours in patients and in rodents

1 reference

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

21 January 2018

1 reference

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

31 March 2020

1 reference

Taming vessels to treat cancer

31 March 2020

1 reference

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

31 March 2020

1 reference

Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy

31 March 2020

1 reference

Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody

31 March 2020

1 reference

Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor

31 March 2020

1 reference

Tumour biology: herceptin acts as an anti-angiogenic cocktail.

31 March 2020

1 reference

Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors

31 March 2020

1 reference

Transplacental carcinogenesis by stilbestrol

31 March 2020

1 reference

Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study

31 March 2020

1 reference

Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas

31 March 2020

1 reference

Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin

31 March 2020

1 reference

Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab

31 March 2020

1 reference

Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer

31 March 2020

1 reference

Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients

31 March 2020

1 reference

Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study.

31 March 2020

1 reference

Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy

31 March 2020

1 reference

Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer a

31 March 2020

1 reference

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

31 March 2020

1 reference

Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours

31 March 2020

1 reference

Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor.

31 March 2020

1 reference

Correlation of relative permeability and relative cerebral blood volume in high-grade cerebral neoplasms.

31 March 2020

1 reference

Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer

31 March 2020

1 reference

A phase I surrogate endpoint study of SU6668 in patients with solid tumors.

31 March 2020

1 reference

Lymphatic metastasis in the absence of functional intratumor lymphatics

31 March 2020

1 reference

Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients

31 March 2020

1 reference

A protocol for phenotypic detection and enumeration of circulating endothelial cells and circulating progenitor cells in human blood

31 March 2020

1 reference

Potentiation of cyclophosphamide chemotherapy using the anti-angiogenic drug thalidomide: importance of optimal scheduling to exploit the 'normalization' window of the tumor vasculature

31 March 2020

1 reference

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

31 March 2020

1 reference

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

31 March 2020

1 reference

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

31 March 2020

1 reference

Sorafenib in advanced clear-cell renal-cell carcinoma

31 March 2020

1 reference

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

31 March 2020

1 reference

Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer

31 March 2020

1 reference

Angiogenesis in life, disease and medicine

31 March 2020

1 reference

Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal cancer

31 March 2020

1 reference

Lessons from phase III clinical trials on anti-VEGF therapy for cancer

31 March 2020

1 reference

Antiangiogenic therapy: a universal chemosensitization strategy for cancer?

31 March 2020

1 reference

Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition

31 March 2020

1 reference

Discovery of vascular permeability factor (VPF).

31 March 2020

1 reference

Angiogenesis in brain tumours

31 March 2020

1 reference

Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration

31 March 2020

1 reference

Antiangiogenic therapy for normalization of atherosclerotic plaque vasculature: a potential strategy for plaque stabilization

31 March 2020

1 reference

Vessels of death or life.

31 March 2020

1 reference

Angiogenesis: an organizing principle for drug discovery?

31 March 2020

1 reference

Barriers to drug delivery in solid tumors

31 March 2020

1 reference

Geometric resistance and microvascular network architecture of human colorectal carcinoma

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRC2346

1 reference

18 August 2017

1 reference

PubMed ID

18337733